Author Archives: admin


MODY: A Rare but Increasingly Common Form of Diabetes – Healthline

It wasnt until a quarter century after being diagnosed with type 1 diabetes (T1D) that Lori Salsbury in Arkansas realized the condition shed been living with since she was 15 years old might not be what she thought it was.

Though her mom and sister were both initially misdiagnosed with type 2 diabetes (T2D) and later correctly dubbed T1Ds, Lori didnt have a reason at first to be suspicious of her own T1D diagnosis. Not until 2015, when she began seeing more people with diabetes sharing their stories online and realized something was off for her.

Sure, there is a mantra in our community that Your Diabetes May Vary. But for Salsbury, the particulars of her T1D just didnt match what she saw others in the D-Community sharing or what doctors and nurses described as the symptoms most newly diagnosed T1D experience.

At the time of her diagnosis, Salsbury was in her mid-20s and seemed quite healthy. She didnt get nauseous or sick, even a full day after missing an insulin dose. Her insulin dosing needs would change frequently, often sending her into super high glucose levels for weeks until adjusting her insulin or carb ratios; the same would happen on the low end of the scale.

One day, Salsbury heard about a rare, inherited form of diabetes called MODY (maturity onset diabetes of the young), that doesnt require as much insulin, at least initially. That piqued her interest.

She did some online research, and then consulted her endocrinologist and received antibody tests that came back negative. He also ran a C-peptide test that came back at T1D levels, but that was most likely due to her 20+ years of using insulin. A referral to a geneticist led to more bloodwork, and in January 2020 the findings came back showing a genetic mutation, which causes one of the several different known types of MODY.

MODY has the potential of changing how you manage your diabetes, depending on the particular form youre diagnosed with. Some changes could include stopping medications completely or changing from insulin to a different injectable or oral medication, while some MODY forms mandate changes in your diet.

In Salsburys case, the MODY diagnosis brought her some clarity, and finally an explanation of why her diabetes experience seemed so different than others in the T1D community. But she continues insulin therapy.

Since I was originally diagnosed T1D, I am still (labeled that) in my charts so that I wont lose coverage for my insulin pump and CGM that I require to live by, Salsbury said. Most often, if asked I just tell people that I was diagnosed with type 1. Its easier than going through the whole What is MODY? spiel.

The easiest way to think about MODY is that its a subset of diabetes caused by a mutation in one of at least 14 genes in a persons DNA. That mutation impacts the insulin-producing beta cells, which in turn impacts insulin production and glucose regulation.

Since just an estimated 1 to 2 percent of those with diabetes have a genetic mutation leading to MODY, there isnt much discussion about it within the patient community, and most medical professionals dont bring it up unless they are questioned. Yet some advocates and researchers believe the various types of MODY are more common than many think, and that view is becoming more accepted as genetic testing becomes more widely available.

The term MODY was first coined in the 1970s by pioneering researchers who identified what appeared to be a mild form of diabetes in children that didnt necessarily require insulin as was needed for those with the more common juvenile diabetes (before it was later renamed type 1). At that time, MODY was defined as fasting hyperglycemia diagnosed under age 25 which could be treated without insulin for more than two years, and it is inherited, as they found.

While most research existing shows its as rare as 1 to 2 percent of all diabetes cases, more current research now indicates that as many as 6.5 percent of children with antibody-negative diabetes may have a form of MODY.

MODY is passed down genetically from parent to child, making that the common thread for this form of diabetes compared to the other types that are autoimmune, partially genetic, or more lifestyle-based. The typical diagnosis comes before age 25, and its rarely diagnosed in those older than 35 or 40. While children have roughly a 50 percent chance of developing MODY if one of their parents has it, that does not mean mutations cant occur at random and appear in those without a family history of gene mutation.

The gene mutations arent the same for everyone, and they affect different organs in the body, meaning its difficult to diagnose without genetic testing, and it can be more challenging to recognize glucose fluctuations commonly found in those who are newly diagnosed.

Significantly, 80 percent of MODY cases are misdiagnosed as T1D or T2D as the signs are pretty much the same extreme thirst, increased urination, and weight loss. But some forms of MODY do not produce any symptoms. The number of misdiagnoses may be even higher at 95 percent in the United States, according to some researchers.

Dr. Miriam Udler at Massachusetts General Hospital is one of the more well-known names in MODY clinical research. She believes more cases are being diagnosed in recent years as genetic testing has become more available, particularly after COVID-19 led to a telehealth explosion and more at-home testing kits for bloodwork and diagnostic tests normally done in a lab.

Dr. Miriam Udler

It used to be rare and expensive, and that was a barrier to testing and diagnosing MODY correctly, she told DiabetesMine. But now, more providers have access to this and can order the tests to their clinics or patients at home, and insurance is increasingly covering MODY genetic testing.

While MODY is still less common and infrequently discussed in clinics, Udler says it comes down to that particular doctor or patient recognizing something might be different about their diabetes.

That matters a lot, and a correct diagnosis can change management, Udler said. In most common MODY forms, it could mean coming off medication.

For Salsbury, the particular BLK gene mutation she has causes MODY 11, an insulin secretion defect that makes her beta cells less responsive to glucose and leads to less insulin being sent out by the body when its needed. Being overweight is one common feature of this particular gene mutation, according to research.

Once MODY is recognized and diagnosed, it can also be difficult to regulate glucose levels in the same ways that T1D and T2Ds often do, because the symptoms and glucose levels can vary significantly.

As MODY 11 usually presents like T1D and is treated in much the same way, Salsbury has been using insulin since she was diagnosed at age 15 in 1991 and wears an Omnipod tubeless insulin pump and Dexcom CGM, combined into a homemade do-it-yourself (DIY) closed loop system. For her, life with MODY isnt much different from being T1D.

But she knows everyone is not as fortunate on that front and can have many challenges in getting a correct diagnosis and finding a management routine that works for their particular form of MODY.

In New York, Laurie Jones shares her story of being diagnosed at 30 with gestational diabetes late in her first pregnancy through the test often given to pregnant women. She changed her diet and followed it to the letter on exact carb and calorie allowances, and took varying doses of long and short-acting insulins. Though she describes it as intense, all signs of diabetes went away after her first pregnancy.

But within a few years during her second pregnancy, gestational diabetes returned. She began insulin injections right away as well as a strict diet, but Jones found it more difficult than before to regulate high and low blood sugars.

A number of years later, her A1C results were creeping higher and that led to a T2D diagnosis. She took Metformin on the advice of her doctor, but it didnt work to keep her blood sugars in check.

Most adult medicine endos do not push for MODY testing even when the medicine is not working, she explained. Being overweight is usually assumed the reason, therefore even star doctors dont push for MODY testing unless weight is lost.

Her sons diagnosis changed everything. When he was 6 years old, he was diagnosed with eosinophilic esophagitis, and that mandated a diet free of the top allergens. He was about 12 when she took him to an endocrinologist, as he was not growing and low on the weight scale and didnt show any signs of puberty. That endo noticed his blood sugars were elevated and assumed he was in the honeymoon period prior to becoming a fully diagnosed T1D.

Months progressed, and the doctor suggested it was MODY. Genetic testing led to a MODY 2 diagnosis.

We had no idea what that was, and before [the doctor] explained it to us, she noted that most endocrinologists and almost all doctors outside of major medical teaching and research hospitals have not heard of it, the D-Mom said.

After her sons diagnosis, Jones got her own genetic testing and learned she also had MODY 2.

Most controlled by diet, MODY 2 is one of the more common but less intensive forms of MODY that usually doesnt require insulin or other glucose-lowering meds.

That led her to stopping Metformin, and shes been eating healthier and managing her weight for better glucose levels.

MODY 2 is not just about how you produce or use insulin, but mainly when you produce the insulin, she said. We were both told that our pancreas is like a house cooling or heating system that is off-kilter. Basically, our sugar levels have to get much higher than what is considered normal before the pancreas produces insulin. There are also insulin efficiency issues.

Without her sons diagnosis, Jones doesnt think she wouldve ever had the needed genetic testing and would have remained with a T2D diagnosis taking the wrong medications.

Thats likely the story for so many people in our D-Community, she believes.

With a 50 percent chance of being passed on, chances are MODY is not as rare as it is now believed, Salsbury said. If more people knew of it and were tested, we may come to find out that it is the most common or second only to T2D in commonality.

Importantly, a correct MODY diagnosis can highlight other health issues that might potentially arise. For example, a MODY 11 mutation to the BLK gene can increase the chances of developing systemic lupus erethematosus (SLE).

While being correctly diagnosed as MODY may not change your treatment, it can give you other information, Salsbury said. Many forms of MODY also come along with other health issues that the mutation may have caused. Knowing you have MODY can alert your doctors to watch you or check you for other related health conditions.

Researchers note the same, including Dr. Toni Pollin, a genetic researcher and counselor who in 2016 co-founded the Monogenic Diabetes Research and Advocacy Project (MDRAP) at the University of Maryland School of Medicine. The MDRAP effort promotes the correct diagnosis of MODY and also helps raise money for that effort. She co-founded MDRAP with a patient advocate whod been diagnosed with a form of MODY.

While improving MODY diagnosis will certainly improve the clinical care for patients, it will also have broader implications, researchers wrote in this 2015-published Undiagnosed MODY: Time for Action manuscript. Screening and genetic testing for MODY among patients with diabetes will provide a model for identifying and diagnosing highly penetrant forms of other otherwise common complex diseases [through] the power of genetics and genomics for improving patient care and public health.

View post:
MODY: A Rare but Increasingly Common Form of Diabetes - Healthline

Eggschain, Pioneering Chain of Custody Solution for Fertility Treatments and Other Biospecimens, Officially First Healthcare Biotech on Bitcoin…

AUSTIN, Texas--(BUSINESS WIRE)--Eggschain, the pioneering authority in blockchain-based digital chain of custody tracking of blood, genome, tissues, organs, DNA, RNA, sperm, eggs, embryos, and other biospecimens, is making history again.

On November 24th, 2021, Eggschain founder and CEO Wei Escala made history by storing her eggs on the blockchain, doing so through the platform she created. Working with Dr. Hugh Taylor, Chair of Obstetrics, Gynecology and Reproductive Sciences at Yale School of Medicine, his team of physicians and nurses, as well as the Eggschain team, Wei underwent egg retrieval on the 24th of November. She entered her data through the Eggschain platform and broadcasted to the blockchain, once Yale School of Medicine verified the accuracy of the data on the same day through the platform.

This is an exciting milestone for the field of fertility preservation, said Dr. Taylor. A reliable and confidential tracking system will allow us to assure the safety and quality of frozen reproductive tissue. Eggschain enables greater transparency and security for patients and health professionals.

Earlier this month, Eggschain successfully generated a bitcoin cryptographic block hash, becoming the first biotech healthcare company on the mainnet. The first patented supply chain system that combines blockchain and genetics to bring secure, transparent, and professional grade information and data to individuals undergoing IVF. Eggschain was developed on Stacks, a collection of independent entities, developers, and community members working to build a user-owned internet on Bitcoin.

Eggschain will mark these dual milestones with an NFT drop that celebrates the arrival of Babies on the Blockchain. The first NFT, Into the Light, shows the meeting of sperm and egg as a light projection on a dark sky, an evocative illustration of the art and science of IVF and the potential for future life. Eggschain will open a whitelist with 2,000 spots in early 2022, with approximately 2,500 to 10,000 NFTs to be released.

Fertility treatment is emotionally and physically demanding, often creating stress and a sense of isolation along the way, said Ms. Escala. By sharing my Eggschain experience, I hope to begin to build a sense of community that help others undergoing fertility treatments feel less alone and more empowered. By delivering medical grade information in a secure and universally trackable format, Eggschain provides transparency and peace of mind, holding the potential to forever change that dynamic for the better.

For further information about Eggschain, please visit https://eggschain.com/.

About Eggschain, INC.

Eggschain is a healthcare technology company and thought leader in the fertility, health tech, family-building and cryogenic preservation industries. Patent-granted and cloud-based, Eggschain is the first blockchain-integrated inventory management and chain of custody technology for tracking biospecimens, including sperm, eggs, embryos, genome, stem cell, tissues and organs, and other genetic material. In partnership with several of the worlds leading experts in reproductive biology, endocrinology and high complexity labs, Eggschain delivers medical grade information and data to individuals undergoing IVF in a secure, transparent and universally trackable format and also provides the means for clinics to monitor their inventory, either personal, such as oocytes and sperm, or lab-related, including equipment inventory and maintenance scheduling. At its core, Eggschain strives to enable better decision-making, preserving the hope of life and helping to advance humanity.

About Stacks

Secure smart contracts and apps for Bitcoin. The Stacks ecosystem is a collection of independent entities, developers, and community members working to build a user-owned internet on Bitcoin. The Stacks 2.0 blockchain extends the design of Bitcoin to enable secure apps and predictable Clarity smart contracts without modifying Bitcoin itself, opening innovation on the network for the first time. The Stacks cryptocurrency (STX) is used as fuel for networking activity and contract execution and can be locked by STX holders via Stacking to earn Bitcoin (BTC) rewards for supporting blockchain consensus. Stacks cryptocurrency was distributed to the general public through the first-ever SEC qualified token offering in U.S. history.

The rest is here:
Eggschain, Pioneering Chain of Custody Solution for Fertility Treatments and Other Biospecimens, Officially First Healthcare Biotech on Bitcoin...

Cancer Stem Cell Therapy Market opportunities, threats, main drivers, and key restraints and COVID-19 analysis to 2026 | Advanced Cell Diagnostics,…

Cancer Stem Cell Therapy Market

The report named Global Cancer Stem Cell Therapy Marketby Worldwide Market Reports offers a profound comprehension of the development and working of the global market on a worldwide just as a local premise. This qualitative report is the gathering of all the extensive information relevant to the market elements over the previous years alongside a few estimates. First and foremost, the market report incorporates the key market players including producers, organizations, associations, providers, etc. This will help the purchasers to understand the methodologies and activities taken up by these players to set a solid foot and spotlight on battle rivalry inside the worldwide Cancer Stem Cell Therapy market.

Request a Sample Copy of Cancer Stem Cell Therapy Market with statistical info @https://www.worldwidemarketreports.com/sample/521057

The Cancer Stem Cell Therapy Market Report is an accurate and thorough cut-out study aimed at key drivers, market strategies, and the huge growth of the major players. Globally, Cancer Stem Cell Therapy Industry also provides in-depth studies of dynamics, segmentation, revenue, and stock forecasting, enabling you to make superior business decisions. The report provides compelling statistics on the market size of major manufacturers and is a vital source of advice and guidance for companies and individuals operating in the Cancer Stem Cell Therapy industry.

Competitive Section:

Major Key Players in the Cancer Stem Cell Therapy Market:

AVIVA BioSciences, AdnaGen, Advanced Cell Diagnostics, Silicon Biosystems

NOTE: Consumer behavior has changed within all sectors of society amid the COVID-19 pandemic. Industries on the other hand will have to restructure their strategies in order to adjust to the changing market requirements. This report offers you an analysis of the COVID-19 impact on the Cancer Stem Cell Therapy market and will help you in strategizing your business as per the new industry norms.

COVID-19 Impact

The report covers the Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Cancer Stem Cell Therapy market in 2021. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans, and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

Get Discount on this Report athttps://www.worldwidemarketreports.com/discount/521057

Regional Analysis:

The report provides information about the market area, which is further subdivided into sub-regions and countries. In addition to market share in each country and subregion, this chapter of this report also provides information on profit opportunities. This chapter of the report mentions the share and market growth rate of each region, country, and sub-region in the estimated time period.

North America (USA, Canada) Europe (Germany, France, UK, Italy, Russia, Spain, Netherlands, Switzerland, Belgium) Asia Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Vietnam) The Middle East and Africa (Turkey, Saudi Arabia, UAE, South Africa, Israel, Egypt, Nigeria) Latin America (Brazil, Mexico, Argentina, Colombia, Chile, Peru).

By Type

Autologous Stem Cell Transplants, Allogeneic Stem Cell Transplants, Syngeneic Stem Cell Transplants, Others

By Application

Hospital, Clinic, Medical Research Institution, Others

Click Here For Inquiry:https://www.worldwidemarketreports.com/quiry/521057

Some of the crucial questions answered in the professional intelligence study on the Cancer Stem Cell Therapy market include:

Which key regions are likely to have the largest share of the Cancer Stem Cell Therapy market? What are the potential obstacles for new players looking to enter the market? What changes has consumer buying behavior observed during the Covid-19 pandemic? Which end consumer industries are likely to drive the demand in the Cancer Stem Cell Therapy market during the forecast period? Which countries are among the main consumers or manufacturers of the Cancer Stem Cell Therapy market? What are the threats and opportunities for stakeholders and market players? Which regions offer lucrative investment opportunities for industry players in the Cancer Stem Cell Therapy Market? What is the type of competition in the market? Which large established companies have the largest share of the Cancer Stem Cell Therapy market? What strategies are these key players pursuing to maintain their dominant position in the Cancer Stem Cell Therapy market?

Please contact us if you would like more information about the report. If you have any special requirements and would like customization, please let us know. We will then offer the report as you wish.

Key Indicators Analysed:

Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2021 & Sales by Product Types.

Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2022-2026. Further, the report provides breakdown details about each region & countries covered in the report. Identifying its production, consumption, import & export, sales volume & revenue forecast.

Market Analysis by Product Type: The report covers the majority of Product Types in the Cancer Stem Cell Therapy Industry, including its product specifications by each key player, volume, sales by Volume, and Value (M USD).

Market Analysis by Application Type: Based on the Cancer Stem Cell Therapy Industry and its applications, the market is further sub-segmented into several major Applications of its industry. It provides you with the market size, CAGR & forecast by each industry application.

Market Trends: Market key trends include Increased Competition and Continuous Innovations.

Opportunities and Drivers: Identifying the Growing Demands and New Technology

Porters Five Force Analysis: The report will provide the state of competition in the industry depends on five basic forces: the threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

Purchase a copy of Cancer Stem Cell Therapy Market research report@:https://www.worldwidemarketreports.com/buy/521057

Contact Us: Worldwide Market Reports, USA: +1-415-871-0703 UK: +44-203-289-4040 Japan: +81-50-5539-1737 Email: sales@worldwidemarketreports.com Website: https://www.worldwidemarketreports.com

Read the original here:
Cancer Stem Cell Therapy Market opportunities, threats, main drivers, and key restraints and COVID-19 analysis to 2026 | Advanced Cell Diagnostics,...

Stem cells: Sources, types, and uses – Medical News Today

Cells in the body have specific purposes, but stem cells are cells that do not yet have a specific role and can become almost any cell that is required.

Stem cells are undifferentiated cells that can turn into specific cells, as the body needs them.

Scientists and doctors are interested in stem cells as they help to explain how some functions of the body work, and how they sometimes go wrong.

Stem cells also show promise for treating some diseases that currently have no cure.

Stem cells originate from two main sources: adult body tissues and embryos. Scientists are also working on ways to develop stem cells from other cells, using genetic reprogramming techniques.

A persons body contains stem cells throughout their life. The body can use these stem cells whenever it needs them.

Also called tissue-specific or somatic stem cells, adult stem cells exist throughout the body from the time an embryo develops.

The cells are in a non-specific state, but they are more specialized than embryonic stem cells. They remain in this state until the body needs them for a specific purpose, say, as skin or muscle cells.

Day-to-day living means the body is constantly renewing its tissues. In some parts of the body, such as the gut and bone marrow, stem cells regularly divide to produce new body tissues for maintenance and repair.

Stem cells are present inside different types of tissue. Scientists have found stem cells in tissues, including:

However, stem cells can be difficult to find. They can stay non-dividing and non-specific for years until the body summons them to repair or grow new tissue.

Adult stem cells can divide or self-renew indefinitely. This means they can generate various cell types from the originating organ or even regenerate the original organ, entirely.

This division and regeneration are how a skin wound heals, or how an organ such as the liver, for example, can repair itself after damage.

In the past, scientists believed adult stem cells could only differentiate based on their tissue of origin. However, some evidence now suggests that they can differentiate to become other cell types, as well.

From the very earliest stage of pregnancy, after the sperm fertilizes the egg, an embryo forms.

Around 35 days after a sperm fertilizes an egg, the embryo takes the form of a blastocyst or ball of cells.

The blastocyst contains stem cells and will later implant in the womb. Embryonic stem cells come from a blastocyst that is 45 days old.

When scientists take stem cells from embryos, these are usually extra embryos that result from in vitro fertilization (IVF).

In IVF clinics, the doctors fertilize several eggs in a test tube, to ensure that at least one survives. They will then implant a limited number of eggs to start a pregnancy.

When a sperm fertilizes an egg, these cells combine to form a single cell called a zygote.

This single-celled zygote then starts to divide, forming 2, 4, 8, 16 cells, and so on. Now it is an embryo.

Soon, and before the embryo implants in the uterus, this mass of around 150200 cells is the blastocyst. The blastocyst consists of two parts:

The inner cell mass is where embryonic stem cells are found. Scientists call these totipotent cells. The term totipotent refer to the fact that they have total potential to develop into any cell in the body.

With the right stimulation, the cells can become blood cells, skin cells, and all the other cell types that a body needs.

In early pregnancy, the blastocyst stage continues for about 5 days before the embryo implants in the uterus, or womb. At this stage, stem cells begin to differentiate.

Embryonic stem cells can differentiate into more cell types than adult stem cells.

MSCs come from the connective tissue or stroma that surrounds the bodys organs and other tissues.

Scientists have used MSCs to create new body tissues, such as bone, cartilage, and fat cells. They may one day play a role in solving a wide range of health problems.

Scientists create these in a lab, using skin cells and other tissue-specific cells. These cells behave in a similar way to embryonic stem cells, so they could be useful for developing a range of therapies.

However, more research and development is necessary.

To grow stem cells, scientists first extract samples from adult tissue or an embryo. They then place these cells in a controlled culture where they will divide and reproduce but not specialize further.

Stem cells that are dividing and reproducing in a controlled culture are called a stem-cell line.

Researchers manage and share stem-cell lines for different purposes. They can stimulate the stem cells to specialize in a particular way. This process is known as directed differentiation.

Until now, it has been easier to grow large numbers of embryonic stem cells than adult stem cells. However, scientists are making progress with both cell types.

Researchers categorize stem cells, according to their potential to differentiate into other types of cells.

Embryonic stem cells are the most potent, as their job is to become every type of cell in the body.

The full classification includes:

Totipotent: These stem cells can differentiate into all possible cell types. The first few cells that appear as the zygote starts to divide are totipotent.

Pluripotent: These cells can turn into almost any cell. Cells from the early embryo are pluripotent.

Multipotent: These cells can differentiate into a closely related family of cells. Adult hematopoietic stem cells, for example, can become red and white blood cells or platelets.

Oligopotent: These can differentiate into a few different cell types. Adult lymphoid or myeloid stem cells can do this.

Unipotent: These can only produce cells of one kind, which is their own type. However, they are still stem cells because they can renew themselves. Examples include adult muscle stem cells.

Embryonic stem cells are considered pluripotent instead of totipotent because they cannot become part of the extra-embryonic membranes or the placenta.

Stem cells themselves do not serve any single purpose but are important for several reasons.

First, with the right stimulation, many stem cells can take on the role of any type of cell, and they can regenerate damaged tissue, under the right conditions.

This potential could save lives or repair wounds and tissue damage in people after an illness or injury. Scientists see many possible uses for stem cells.

Tissue regeneration is probably the most important use of stem cells.

Until now, a person who needed a new kidney, for example, had to wait for a donor and then undergo a transplant.

There is a shortage of donor organs but, by instructing stem cells to differentiate in a certain way, scientists could use them to grow a specific tissue type or organ.

As an example, doctors have already used stem cells from just beneath the skins surface to make new skin tissue. They can then repair a severe burn or another injury by grafting this tissue onto the damaged skin, and new skin will grow back.

In 2013, a team of researchers from Massachusetts General Hospital reported in PNAS Early Edition that they had created blood vessels in laboratory mice, using human stem cells.

Within 2 weeks of implanting the stem cells, networks of blood-perfused vessels had formed. The quality of these new blood vessels was as good as the nearby natural ones.

The authors hoped that this type of technique could eventually help to treat people with cardiovascular and vascular diseases.

Doctors may one day be able to use replacement cells and tissues to treat brain diseases, such as Parkinsons and Alzheimers.

In Parkinsons, for example, damage to brain cells leads to uncontrolled muscle movements. Scientists could use stem cells to replenish the damaged brain tissue. This could bring back the specialized brain cells that stop the uncontrolled muscle movements.

Researchers have already tried differentiating embryonic stem cells into these types of cells, so treatments are promising.

Scientists hope one day to be able to develop healthy heart cells in a laboratory that they can transplant into people with heart disease.

These new cells could repair heart damage by repopulating the heart with healthy tissue.

Similarly, people with type I diabetes could receive pancreatic cells to replace the insulin-producing cells that their own immune systems have lost or destroyed.

The only current therapy is a pancreatic transplant, and very few pancreases are available for transplant.

Doctors now routinely use adult hematopoietic stem cells to treat diseases, such as leukemia, sickle cell anemia, and other immunodeficiency problems.

Hematopoietic stem cells occur in blood and bone marrow and can produce all blood cell types, including red blood cells that carry oxygen and white blood cells that fight disease.

People can donate stem cells to help a loved one, or possibly for their own use in the future.

Donations can come from the following sources:

Bone marrow: These cells are taken under a general anesthetic, usually from the hip or pelvic bone. Technicians then isolate the stem cells from the bone marrow for storage or donation.

Peripheral stem cells: A person receives several injections that cause their bone marrow to release stem cells into the blood. Next, blood is removed from the body, a machine separates out the stem cells, and doctors return the blood to the body.

Umbilical cord blood: Stem cells can be harvested from the umbilical cord after delivery, with no harm to the baby. Some people donate the cord blood, and others store it.

This harvesting of stem cells can be expensive, but the advantages for future needs include:

Stem cells are useful not only as potential therapies but also for research purposes.

For example, scientists have found that switching a particular gene on or off can cause it to differentiate. Knowing this is helping them to investigate which genes and mutations cause which effects.

Armed with this knowledge, they may be able to discover what causes a wide range of illnesses and conditions, some of which do not yet have a cure.

Abnormal cell division and differentiation are responsible for conditions that include cancer and congenital disabilities that stem from birth. Knowing what causes the cells to divide in the wrong way could lead to a cure.

Stem cells can also help in the development of new drugs. Instead of testing drugs on human volunteers, scientists can assess how a drug affects normal, healthy tissue by testing it on tissue grown from stem cells.

Watch the video to find out more about stem cells.

There has been some controversy about stem cell research. This mainly relates to work on embryonic stem cells.

The argument against using embryonic stem cells is that it destroys a human blastocyst, and the fertilized egg cannot develop into a person.

Nowadays, researchers are looking for ways to create or use stem cells that do not involve embryos.

Stem cell research often involves inserting human cells into animals, such as mice or rats. Some people argue that this could create an organism that is part human.

In some countries, it is illegal to produce embryonic stem cell lines. In the United States, scientists can create or work with embryonic stem cell lines, but it is illegal to use federal funds to research stem cell lines that were created after August 2001.

Some people are already offering stem-cells therapies for a range of purposes, such as anti-aging treatments.

However, most of these uses do not have approval from the U.S. Food and Drug Administration (FDA). Some of them may be illegal, and some can be dangerous.

Anyone who is considering stem-cell treatment should check with the provider or with the FDA that the product has approval, and that it was made in a way that meets with FDA standards for safety and effectiveness.

Follow this link:
Stem cells: Sources, types, and uses - Medical News Today

First person cured of type 1 diabetes thanks to stem cells – Freethink

Brian Shelton wept.

He checked his blood sugar, ate a meal with his ex-wife, checked his blood sugar again, and wept.

His insulin levels were perfect. The type 1 diabetes that had caused him to crash his motorcycle, faint in a yard, and forced him to retire from the postal service, was gone.

The diabetes cure was an infusion of stem cells that turned into the type of cells the body needs to produce insulin cells that had never worked in his life before.

Its a whole new life, Shelton told the New York Times Gina Kolata. Its like a miracle.

In just the year before Sheltons treatment, he had suffered five severe, potentially life-threatening episodes of low blood sugar, USA Today reported.

Now, Sheltons dramatic results have those in the field cautiously optimistic that Sheltons stem cell-based procedure could be a cure for diabetes.

The dramatic results have those in the field cautiously optimistic that stem cell-based procedures could be a cure for type 1 diabetes.

Type 1 diabetes: Diabetes comes in two varieties that lead to the same problem: the body cannot keep its blood sugar levels in the right place. In the case of type 2 diabetes, the most common form of the disease, the body does not utilize insulin correctly.

In the case of type 1 diabetes, like Shelton had, the body is wholly missing the cells that create insulin. Called islet cells and found in the pancreas, type 1 diabetes appears to be caused by the immune system wiping them out.

Type 1 diabetes can prove lethal in short order if patients do not receive injections of insulin, and it can cause amputation, kidney transplants, and blindness.

Artificial insulin is the standard treatment, but it can be extremely expensive, and artificial pancreases which have now been approved for children can make managing the condition easier, but are not a cure for diabetes.

There is a known type 1 diabetes cure: transplanting islet cells from a donors pancreas, or the whole pancreas. But it is far from practical there just arent enough healthy, donated pancreases out there.

Which is why Sheltons stem cell results have researchers optimistic but guarded.

It is a remarkable result, UCLA diabetes expert Peter Butler, who was not involved in the trial, told Kolata. To be able to reverse diabetes by giving them back the cells they are missing is comparable to the miracle when insulin was first available 100 years ago.

To develop the treatment, researchers had to reverse-engineer how the body grows the pancreas to begin with.

A dad vs. diabetes: The stem cell treatment Shelton received this past June is the result of decades of work by biologist Doug Melton, who began work on a cure after his kids developed type 1 diabetes.

Melton looked to embryonic stem cells as a potential diabetes cure. Stem cells have the capability to become any kind of cell including islet cells. But coaxing them to become functional insulin-producing cells took decades of trial and error.

Meltons small team had to figure out which chemical signals, in what order, work to create islet cells, Kolata explains; in essence, they needed to reverse-engineer how the body grows the pancreas to begin with.

In 2014, they found it: their stem cell-derived islet cells began producing insulin. They worked as a diabetes cure in rodents. After his company was acquired by Vertex Pharmaceuticals, it was time for the next step: human trials.

Shelton was patient number one.

A cure with a cost: Shelton was infused with the cells, which soon went to work producing insulin and regulating his blood sugar, curing his diabetes. While the results are exciting, aside from the fact its only one patient so far, its not a silver bullet.

Chief among the concerns is rejection. Just like in an organ transplant, an infusion of embryonic stem cells means Shelton needs to take immune system-suppressing drugs to ensure his body doesnt attack the foreign cells. Shelton told Kolata the immunosuppressive regimen causes him no issues, so far, and its much easier to deal with than not making insulin, but it is something to keep an eye on.

Vertex is also looking to run future studies using our encapsulated islet cells, which hold the potential to be used without the need for immunosuppression, Bastiano Sanna, executive VP, said.

The success of a similar technique in Canada is a sign of hope that an outright cure for diabetes may be coming soon.

The study Shelton is involved in is on-going, taking place over five years and enrolling an estimated 17 patients; according to their study listing, Vertex does not expect to complete the study until 2028.

Experts told Kolata that they want to see the results of the trial thus far, which has not yet been peer-reviewed and published. Only further research will suss out if adverse events may arise, or if the treatment is temporary.

Not alone: Sheltons news comes as a team at the University of British Columbia has announced similar promising results, GEN reports.

Patients in the Canadian study, which has been published in Cells Stem Cell journal, used a different type of stem cell, surgically implanted on small, credit-card thick devices.

Our findings demonstrate the incredible potential of this stem cell-based treatment. With further research, this treatment could one day eliminate dependence on insulin injections and transform the management of Type 1 diabetes, UBC professor Timothy Kieffer, the study lead author, said.

While the UBC patients did not produce enough insulin to eliminate their need for it, the follow up period, which lasted up to a year, found that their insulin requirements had decreased by 20%, and they spent 13% more time in their optimal blood sugar window.

Still, the success of a similar technique in Shelton is a sign of hope that an outright cure for diabetes may be coming soon.

When Melton told his family the results, they wept, too.

Wed love to hear from you! If you have a comment about this article or if you have a tip for a future Freethink story, please email us at tips@freethink.com.

View post:
First person cured of type 1 diabetes thanks to stem cells - Freethink

City of Hope to buy Cancer Treatment Centers of America for $390M – Modern Healthcare

City of Hope, a prominent not-for-profit cancer researcher and treatment provider, said Wednesday it plans to buy Cancer Treatment Centers of America.

The deal, expected to close early next year pending regulatory approval, would create a large network of inpatient and outpatient oncology care that would serve an estimated 115,000 patients annually. The definitive agreement holds that Duarte, California-based City of Hope would pay $390 million for CTCA, based in Boca Raton, Florida.

"In Cancer Treatment Centers of America, we found an organization that shares with us that nonnegotiable value of putting patients first, the urgency of eliminating cancer and the commitment to delivering high-quality care," City of Hope CEO Robert Stone said in an interview.

The transaction would unite two cancer specialists with decidedly different backgrounds. City of Hope is among 71 National Cancer Institute-designed cancer centers in the country. It's a distinction the federal agency grants to providers that meet rigorous standards for state-of-the-art research focused on improving cancer prevention, diagnosis and treatment. City of Hope is known as a leading cancer researcher, with more than 450 patent portfolios and 95 active investigator-initiated drugs. The provider also runs a large bone marrow and stem cell transplant program.

Dr. Pat Basu, CTCA's CEO, said in an interview he looks forward to granting CTCA's patients access to City of Hope's clinical trials and bone marrow transplant program, which he said is the best in the country. Together, Basu said he thinks the providers will speed up important milestones in cancer research and treatment outcomes.

"Strategically, this a remarkably complementary fit," he said, noting there is no geographic overlap between the providers.

CTCA is a for-profit company with hospitals and outpatient clinics in three metro areas: Atlanta, Chicago and Phoenix. The company sold its hospitals in Philadelphia and Tulsa, Oklahoma earlier this year and has touted a focus on partnerships with health systems that rely heavily on telehealth.

CTCA spent the decade ending in 2016 operating under a federal injunction that barred the company from making unsubstantiated claims in its advertising. The Federal Trade Commission accused CTCA of making false claims regarding its success rates. CTCA cherry-picked patients based on insurance coverage and overhyped the success of its treatments, according to a 2013 Reuters investigation.

"I'm not concerned," Stone said when asked about CTCA's reputation. "I focus more on, frankly: What is it the cancer patients want? Cancer patients want timely access to doctors focused on treating their type of cancer."

City of Hope performed thorough due diligence into CTCA, and Stone said he personally visited the company's facilities in Atlanta and Phoenix. Stone's team emerged convinced that the two companies share the same values, Stone said.

Once the combination is official, City of Hope said it plans to transform CTCA into a not-for-profit organization. Basu will remain CEO of CTCA and will report to Stone. Stone said his team hasn't decided whether they'll pursue NCI designation for CTCA.

The broader goal behind the deal is to make cancer care available to more people, Stone said. Eighty percent of cancer care is currently delivered in community settings, but there's a widening gap between those who get access and those who don't, he said. The combined company would have 575 physicians and more than 11,000 employees across five states.

The deal would expand City of Hope's geographic reach. Its 36 care sites are currently limited to Southern California, in addition to a genomics institute it recently acquired in Phoenix.

Both providers partner directly with employers to offer workers cancer information and support. To that end, City of Hope launched its AccessHope program in 2019, and it now includes 17 Fortune 500 companies.

City of Hope posted a 2.7% operating margin in the nine months ended June 30, up from 0% in the prior-year period. Significant investment income pushed its excess margin to 27% in the 2021 period, when it made almost $700 million on about $2.6 billion in revenue.

As a private, for-profit company, CTCA is not required to disclose information on its financial performance.

Rumors have swirled about a potential CTCA sale since a 2020 report that the company was considering a private equity buy-out. Basu acknowledged there were other potential partners that expressed interest, but said City of Hope is more aligned with CTCA's mission and strategy.

Wednesday's news follows other deal action in the cancer treatment space. Last month, the first publicly traded oncology specialist debuted on the stock market following its merger with a special purpose acquisition company. The Oncology Institute, headquartered in the Los Angeles area, has 50 offices in four states and touts a value-based model of oncology care.

While City of Hope brings cutting-edge research and clinical trials to the table, Basu said CTCA brings a national oncology footprint and a recognizable brand.

"Ultimately I think this is tremendous for patients, it's tremendous for our collective organizations and outstanding for our employees on both sides," he said.

Read more here:
City of Hope to buy Cancer Treatment Centers of America for $390M - Modern Healthcare

The lung game: is hyperbaric oxygen therapy any good? – Financial Times

We typically breathe 25,000 times aday. And were right to be worried about the quality of the air were inhaling. Weve long been concerned about pollution in citiesand Covid has made us focus ever more closely on whats in the air. But is there anywhere or anything we can breathe with impunity? Widely used by athletes, hyperbaric oxygen therapy is linked to benefits ranging from wound healing and long Covid recovery, to improved immunity andbrain function, andeven cellular youth. Footballers Mohamed Salah and Cristiano Ronaldo are fans, as are Michael Phelps and LeBron James and Justin Bieber. Soshould we all sign up?

In HBOT a patient breathes 100 per cent oxygen inapressurised chamber, says Dr Gary Smerdon, CEO ofDDRC Healthcare, a UK-based medical charity that researches diving diseases and provides hyperbaric treatment. The pressure causes the oxygen to dissolve into your blood plasma, he explains; it thereby drives 1,200per cent more oxygen into circulation. A typical solo chamber is a cylindrical pod a bit bigger than an old-school sunbed; its a comfortable enough experience, beyond a slight ear-popping, though not one for the claustrophobic.

Claimed benefits include a lowering of inflammation, aboost in the production of energy in cells throughout the body (via the ATP molecule), an eightfold increase instem-cell circulation (key for repair), enhanced immune function and the formation of new blood vessels. But who derives most from the treatment? Thats controversial. The US Food and Drug Administration and the European Committee of Hyperbaric Medicine have approved 13 conditions for treatment, such as decompression sickness (aka the bends) and non-healing wounds. DDRC Healthcare also treats certain off-label conditions, such asinjuries in professional rugby players. With HBOT, damaged ligaments heal with a more flexiblecollagen, says Smerdon. Some of the UKs leading chambers are designed for racehorses. Given that thebest results start after 20 to 80 hours worth of treatments (which each cost 250), then, says Smerdon, If you are only a weekend warrior, I would say the gainsare too marginal to be worth it.

When it comes to treating long covid, Smerdon says initial findings show promise, but regarding conditions such as ME or fatigue, or using HBOT as an anti-ageing, pro-health hack, he is cautious: Caveat emptor. It may help, but there is no clearly defined evidence. At the same time, he shrugs, getting hard data is challenging, because running the trials is difficult and really expensive. While all the doctors I speak to concur is that HBOT should be done under proper medical supervision (contraindications include certain lung issues) and not simply, says Smerdon, by some high-street beautician, a growing number of unregulated chambersare appearing in the UK.

Do your research and go in with your eyes open

Dr Nur Ozyilmaz is a paediatric consultant who has worked at Kings College Hospital and Great Ormond Street. Her belief in integrative medicine (combining conventional and complementary therapies) has led her to found Numa, a sleek, white hyperbaric centre off Bond Street in London. Each patient is assessed to seeifthey would benefit from treatment; they can present with anything from brain injury to inflammatory bowel disease, and Ozyilmaz has also seen so-called biohackers seeking optimised health and enhanced performance: More and more young City workers come wanting to perform better at work, and often also in sports. Typically they have 20 sessions close together (a 90-minute treatment is 240), then two a week. Iused to discourage them, saying there is no evidence for this kind of approach. It could all be placebo, but they swear it improves their energy levels, sleep and exercise capacity.

Far more patients come with a history of concussion, which has left them with issues such as hormonal imbalances or fatigue, she continues. I am passionate about treating them, as we see such good results. We also see patients with brain fog associated with long Covid, most of whom start reporting improvements from their first few sessions.

Numa will also administer HBOT to older CEOs hoping to sharpen their thinking. This autumn has seen a fresh flurry of interest around HBOT and dementia, with new research concluding it offers multifaceted neuro-protective effects that improve memory and brain function by boosting blood flow and slowing the growth of amyloid plaques in the brain, thought to be connected to Alzheimers. This builds on other studies, such as one that found HBOT induced cognitive enhancements... including information-processing speed and executive functions.

However, says Dr Gary Toups, head of hyperbaric medicine at the Mayo Clinic in Rochester, Minnesota, Ive not seen any significant effect on cognition in patients treated with HBOT. Along with Smerdon, he says more research is needed to investigate whether HBOT may slow down cellular ageing: a widely publicised Israeli study suggested it might, finding that the length of telomeres (the protective caps over the end of our chromosomes, which diminish as we age) increased by more than 20 per cent over a 60-day treatment, and damaging, senescent zombie cells decreased by up to 37 per cent. So far, he says, it is only a single study, the importance of which has yet to be determined.

Do your research and go in with your eyes open, says Smerdon. In off-label treatments, some people get excellent results; for others theres no effect. Ozyilmaz is more optimistic. What excites me about HBOT is the huge potential it offers without drugs or side effects, she says. It looks to a future of medicine where we can harness our bodys own ability to repair and regenerate, to support ourselves to optimal health.

Original post:
The lung game: is hyperbaric oxygen therapy any good? - Financial Times

Cell Culture Media Market is predicted to grow from US$ 2.6 Bn in 2020 to over US$ 5.6 Bn by 2031 – PRNewswire

Demand for cell culture media is increasing with rising production of biopharmaceuticals. Biopharmaceutical drugs are structurally similar to human compounds. This similarity in structure gives biopharmaceuticals the ability to cure diseases rather than only treat the symptoms. Also, biopharmaceuticals have fewer side effects because of their specificity, unlike conventional drugs that affect multiple systems. Biopharma is helping doctors in treating various diseases such as diabetes and cancer, because it allows clinicians to give specialized treatment to the specific medical problems of each patient.

With increasing demand for regenerative medicines, sale of cell culture media also increases. It is because regenerative medicine is that branch of medicine that develops methods to regrow, heal or replace injured or unhealthy cells, organs, and tissues.

Request for sample PDF of report: https://www.persistencemarketresearch.com/samples/31338

Key Takeaways from Market Study

"Increasing production of antibodies for treatment of diseases and rising prevalence of cancer are expected to drive demand of cell culture media over the decade," says a Persistence Market Research analyst.

Get Full TOC of the report: https://www.persistencemarketresearch.com/market-research/cell-culture-media-market/toc

Who is Winning?

Some of the chief manufacturers of cell culture media are focusing on product launches, collaborations, and acquisitions for global expansion objectives, thereby enhancing their market presence.

Key market players covered in this research include GE Healthcare, Thermo Fisher Scientific, Merck KGaA, Lonza, Corning Incorporated, Irvine Scientific, STEMCELL Technologies Inc., and PAN Biotech.

Get Full access of report: https://www.persistencemarketresearch.com/checkout/31338

Want More Valuable Insights?

Persistence Market Research brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global cell culture media Market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

The study provides compelling insights into the cell culture media market. The market is segmented into five parts based on product (serum containing media, serum-free media, protein free media, and chemically defined media) based on application (cancer research, biopharmaceuticals, regenerative medicine & tissue engineering, stem cell technologies, and others) based on the end user (biopharmaceutical companies, clinical research organizations, and academic research centers), and across seven major regions.

Related Reports:

o Cell Tissue Culture Supplies Marketo Stem Cell Therapy Marketo 3D Cell Cultures Market

About Persistence Market Research:

Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.

Overview:

Persistence Market Research is always way ahead of its time. In other words, it tables market solutions by stepping into the companies'/clients' shoes much before they themselves have a sneak pick into the market. The pro-active approach followed by experts at Persistence Market Research helps companies/clients lay their hands on techno-commercial insights beforehand, so that the subsequent course of action could be simplified on their part.

ContactRajendra Singh Persistence Market Research U.S. Sales Office: 305 Broadway, 7th Floor New York City, NY 10007 +1-646-568-7751 United States USA - Canada Toll-Free: 800-961-0353 Email: [emailprotected] Visit Our Website:https://www.persistencemarketresearch.com

SOURCE Persistence Market Research Pvt. Ltd.

Go here to see the original:
Cell Culture Media Market is predicted to grow from US$ 2.6 Bn in 2020 to over US$ 5.6 Bn by 2031 - PRNewswire

It is imperative to reduce the cost of cancer treatment: Ramesh Ramadurai, MD, 3M India – ETHealthworld.com

Shahid Akhter, editor, ETHealthworld, spoke to Ramesh Ramadurai, MD, 3M India, to know more 3M collaborations that can improve and impact cancer care, besides cutting down on the costs in a big way.

How has the technological and infrastructural facilities impacted Bone Marrow Transplantation in India ? Every year nearly 20,000 Indian patients, including many children, who suffer from blood and solid cancers require bone marrow transplantation (BMT). However, only 2,000 of these patients are fortunate enough to receive this therapy, as the cost of bone marrow transplantation can vary from INR 10 Lakhs to 30 Lakhs. It is imperative to reduce the cost of cancer treatment while maintaining a stringent focus on sterilization and quality. It is indeed the need of the hour for us to address this issue.

What are the various technological advancement required for the better functioning of the facilities?Despite the increasing demand for bone marrow transplantation, the number of bone marrow doners in India is astonishingly low. India conducts stem cell transplant procedure for approximately 2,000 every year, while around 80,000 to 100,000 annual transplants are required to tackle the burden of blood cancers and fatal blood disorders. Finding a matching donor is very difficult. This option is exercised only after the alternative options have failed.

India has only about 400,000 donors registered on the bone marrow registry. Chances of finding a donor match are as low as 10% to 15% compared to the West where the chances of matching are as high as 60% to 70% due to higher rates of donations.

What are the major and significant developments in treating bone marrow cancer in the country? A bone marrow registry collects information on individuals willing and able to donate bone marrow and gathers the donor information into a database. In India, organisations like Datri are helping to create a pool of donors to help people who do not have blood-related donors by finding an unrelated match for life-saving treatment.

Infusion of a memory cell is another advancement. This involves taking out the cells, sorting the good cells and the memory cells or the fighting cells, which can fight infections, sorting them out, capturing them and putting them back into the body after giving the requisite chemotherapy. This is also called T-cell depletion with memory cell infusion. It is now available in India and is affordable.

Through this partnership with United Way Bengaluru and Sri Shankara Cancer Hospital and Research Centre (SSCHRC), how does 3M aim to foster accessibility for people from different sections of the society in treating cancer. 3M India was brought into the SSCHRC family through United Way of Bengaluru, and this is our second round of engagement with the hospital. Last year, 3M India had donated equipment for cancer research and diagnostics like the Sanger sequencer and QPCR, made enhancements to the childrens play area at the long-stay Lakshmi Childrens center with child-friendly wall graphics, and provided kitchen utensils and cooking counters for the resident families of paediatric cancer patients.

We have donated several critical equipments for the research labs which contribute to the successful treatment of the BMT patients. As on date the BMT unit at SSCHRC has treated and discharged 5 patients and currently 4 are undergoing treatment. This wing of the hospital is accessible by few staff nurses and specialists like Dr K N Nataraj who is the Chief of Adult and Paediatric Haematology at the hospital. For a successful bone marrow transplantation, there are several requisites, some of which include, successful donor matching, extremely technique-sensitive harvesting and transplantation processes and robust infection control. With this essential, life-saving equipment, the cost of the treatment will reduce to approximately 50% (between Rs 8-12 Lacs as against the actual cost of Rs 15- 30 lacs) and help the hospital treat many more cancer patients.

How do 3M India and Sri Shankara Hospital plan to take this initiative ahead in the future for the growth and enhancement of bone marrow transplantation in the facility? It is matter of pride for 3M India and United Way of Bengaluru that we are associated with SSCHRC, an institution at the forefront of providing comprehensive cancer treatment to the needy, through CSR interventions.

By complying with the Foundation for the Accreditation of Cellular Therapy (FACT) Guidelines, the BMT Centre will be a one-of-a-kind medical facility where people of all economic status can receive treatment. Being a growing facility, the hospital is committed to continuing its responsibility towards expansion of multiple hospital beds and medical care. We are inspired by the commitment of the doctors and Sri Shankara Board of Trustees, led by Dr. B.S. Srinath and other dedicated professionals who developed a multifaceted approach to establishment a state of the art, affordable cancer hospital that is accessible to all irrespective of caste, creed, religion, gender or socioeconomic status.

Read the original:
It is imperative to reduce the cost of cancer treatment: Ramesh Ramadurai, MD, 3M India - ETHealthworld.com

COVID: How bad is the omicron variant? Q&A on what new research is telling us – The Denver Post

The new omicron variant is spreading fast. But research is beginning to catch up.

Because an early case was detected in San Francisco, local scientists have quickly started growing the virus in high-security labs at UC San Francisco, UC Berkeley and Stanford.

Using cell cultures, theyll soon learn how readily it transmits, whether it can dodge our defenses and outcompete delta. In mice, theyll study whether it produces illness that is severe or mild.

In one or two weeks, we will have a much clearer picture of what this variant is going to do to us, said Dr. Melanie Ott of UC San Franciscos Gladstone Institute of Virology and Immunology.

Meanwhile, South Africa studies have begun to offer a real-world glimpse of how much risk omicron poses.

The extent to which omicrons sudden spread is caused by immune evasion or more contagiousness or both is yet unclear. But as the variant expands into 17 U.S. states and at least 45 nations worldwide, heres what were learning:

Q: Is omicron more or less dangerous than delta?

A: A new small study suggests that omicron may cause less severe illness than previous variants like delta.

The best indicator of disease severity is the in-hospital death rate. A report this weekend identified 10 omicron-linked hospital deaths at two South African hospitals, representing about 6% of 166 COVID-related admissions. This compared to a 17% death rate at the hospitals among COVID-19 patients during previous waves of infections. However, this time it wasnt just elders who died; four of the deaths were in adults ages 26 to 36.

The same hospital said that the majority of COVID patients did not need extra oxygen, and far fewer were so sick that they were admitted to the ICU. Most discovered they were infected only after being admitted to the hospital for other health reasons. The average hospital stay was only 2.8 days, down from 8.5 days during infection with other variants.

Most of these patients were unvaccinated, although there were some vaccinated admissions, as well.

Can this be generalized given the younger population in South Africa, with very extensive prior COVID? Thats an uncertainty that will remain until we see much larger numbers of infections in older people.

South African Medical Research Council

Q: Whats the latest guess about how infectious it is?

A: In South Africa, about 3 to 3.5 new omicron infections are estimated to stem from a single case. In contrast, the reproductive rate of delta in South Africa and the U.S. was about 1.5.

If omicrons reproductive rate continues at around 3, this indicates a much larger threat, in terms of case counts, than delta. The size of the wave depends on the susceptible population.

Trevor Bedford, Fred Hutchinson Cancer Research Center in Seattle

Q: Will omicron overtake delta?

A: In South Africa, omicron has surpassed delta as the dominant strain. But delta was on the wane there, so omicron had an open field to run in. Omicron did not have to push delta out.

What we dont know is how well omicron will compete in an environment thats 99.9% delta, such as California.

Dr. Warner Greene, Director of Gladstone Institute of Virology and Immunology, UCSF

Q: If it outcompetes delta, and its milder, isnt that good news?

A: It would be great if omicron is always a mild virus. But we dont know that yet. It will take a month or so to learn the virulence of this variant, and whether it will replace delta.

Dr. Warner Greene

Q: Will my previous infection protect me?

A: Perhaps not. South African doctors are seeing an uptick in reinfections among people who tested positive for the virus at least 90 days earlier, suggesting that immunity acquired through natural infection is not fully protective.

Omicron is three times more likely to cause reinfection compared to delta, according to a Dec. 2 paper.

Juliet Pulliam, director of the South African Centre for Epidemiological Modelling and Analysis, Stellenbosch University

Q: Are vaccines protective against infection?

A: We dont yet know. In infected patients in one very small South African study, more than half were considered fully vaccinated, with two shots.

But its unclear how much time had passed since their inoculation. If it was more than six months, their antibody levels had waned.

These patients hadnt gotten boosters. Boosting creates a huge increase in antibodies much more than what is achieved after the second vaccine dose. Thats what is leading vaccinologists to hope that even if antibody levels start to decline, protection will last longer. Its starting at a much higher level.

Dr. Warner Greene

Q: How long will it take to design omicron-specific vaccines?

A: Vaccine makers Pfizer and Moderna say they can get one ready within 100 days. Making a new mRNA vaccinewill involve generating a new genetic sequence, based on omicron, and encapsulating it in a fatty substance such as a lipid.

This autumn, the vaccine companies have been doing dry runs, practicing all aspects of executing a strain change the preclinical research, the manufacturing, the clinical testing and the regulatory submissions so they are ready to respond quickly.

Journal Nature

Q: Then will we have to wait for new clinical trials and FDA approval?

A: The FDA told the Wall Street Journal that it is already in conversations about streamlining authorization for revamped vaccines. Agency officials have met with vaccine makers and are working to set guidelines for the type of data that will be needed to swiftly evaluate the safety and efficacy of changes to current vaccines.

Wall Street Journal

Q: Should omicron change how we celebrate the holidays?

A: Its probably best to avoid international travel. Its far better to fly domestically than take a long haul flight to Europe, Asia or Africa. And be careful about where you fly domestically. Dont fly into a hot zone.

But experts like Dr. Greene say their perspective is so different this December versus last year. My family and I are vaccinated, he said. I do not believe that Im going to die of this coronavirus. I dont believe my family will die of this coronavirus.

Yes, I may get infected. I might be sick for awhile. But I am really confident that Im not going to die. And that just changes my whole perspective. Were in such a better place.

Dr. Warner Greene

Join our Facebook group for the latest updates on coronavirus in Colorado.

See the original post here:
COVID: How bad is the omicron variant? Q&A on what new research is telling us - The Denver Post